636
Views
11
CrossRef citations to date
0
Altmetric
Clinical Study

Fibroblast Growth Factor 23 is a Predictor of Aortic Artery Calcification in Maintenance Hemodialysis Patients

, , , , , , , , & show all
Pages 660-666 | Received 02 Dec 2012, Accepted 26 Feb 2013, Published online: 15 Apr 2013

REFERENCES

  • KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl.113):S1–S130.
  • Kauppila LI, New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245–250.
  • Honkanen E, Abdominal aortic calcification in dialysis patients: results of the CORD study. Nephrol Dial Transplant. 2008;23(12):4009–4015.
  • Toussaint ND, Lateral lumbar X-ray assessment of abdominal aortic calcification in Australian haemodialysis patients. Nephrology (Carlton). 2011;16(4):389–395.
  • Bellasi A, Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int. 2006;70(9):1623–1628.
  • Russo D, Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis. 2004;44(6): 1024–1030.
  • El-Saed A, The prevalence of aortic calcification in Japanese compared to white and Japanese-American middle-aged men is confounded by the amount of cigarette smoking. Int J Cardiol. January 10, 2012 [Epub ahead of print].
  • London GM, Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731–1740.
  • Okuno S, Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007;49(3):417–425.
  • Jean G, Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24(3):948–955.
  • Inaba M, Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006;17(10):1506–1513.
  • Ix JH, Fibroblast growth factor-23 and early decrements in kidney function: The Heart and Soul Study. Nephrol Dial Transplant. 2010;25(3):993–997.
  • Isakova T, Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. J Am Med Assoc. 2011;305(23):2432–2439.
  • Jean G, High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009;24(9): 2792–2796.
  • Gutierrez OM, Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–592.
  • Holden RM, FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial Int. 2012;16(1):53–58.
  • Canziani ME, Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif. 2011;31(1–3):26–32.
  • Faul C, FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–4408.
  • Seiler S, The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J. 2011;32(21):2688–2696.
  • Nasrallah MM, Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25(8):2679–2685.
  • Isakova T, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–1378.
  • Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011;6(12):2871–2878.
  • Koiwa F, Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial. 2005;9(4):336–339.
  • Gonzalez-Parra E, Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant. 2011;26(8):2567–2571.
  • Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91(8):3144–3149.
  • Burnett SM, Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21(8):1187–1196.
  • Shimada T, Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98(11):6500–6505.
  • Gutierrez O, Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–2215.
  • Torres PU, Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int. 2007;71(8):730–737.
  • Urakawa I, Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–774.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.